

AmpliVue®

Anytime, Anywhere Molecular Assays

C. difficile




For the qualitative detection and identification of toxigenic *Clostridium difficile* bacterial DNA

- Easy-to-read disposable cassette-based molecular testing
- No capital investment
- Minimal hands-on time
- Uniform pipetting volumes
- Total assay time approximately 80 minutes
- Lyophilized reagents

AmpliVue®

Anytime, Anywhere Molecular Assays

Procedure



Why Test?

- Nucleic acid amplification tests can be as much as twice as sensitive as enzyme immunoassays.¹
- *C. difficile* infection (CDI) can range in severity from asymptomatic to life-threatening, especially among the elderly (most often nosocomially infected in hospitals, nursing homes or other medical institutions).²
- Relapses of *C. difficile* have been reported in up to 20% of cases.³ Increases to 40% and 60% with subsequent recurrences.⁴
- *C. difficile* infection often mimics some flu-like symptoms and can mimic disease flare in patients with inflammatory bowel disease associated colitis.⁵

Clinical performance

C. difficile			
Fresh Stool Specimens Received for CDAD Testing (N=835)	Tissue Culture Cytotoxin		
	Positive	Negative	Total
AmpliVue C. difficile Assay			
Positive	102	43*	145
Negative	7**	683	690
Total	109	726	835
	95% CI		
Sensitivity	93.6%	87.3%	96.9%
Specificity	94.1%	92.1%	95.6%

*Of these 43 discordant specimens (AmpliVue Positive/Tissue Culture Cytotoxin Negative) reported, 37 were positive for *C. difficile* by a FDA-cleared molecular device, and 6 were negative.

**Of these 7 discordant specimens (AmpliVue Negative/Tissue Culture Cytotoxin positive) reported, 2 were positive for *C. difficile* by an FDA-cleared molecular device, and 5 were negative.

AmpliVue C. difficile Assay – 16 Test Kit: Catalog #M201
 Quidel Molecular C. difficile Control Set – 10-Reaction Kit: Catalog #M108

¹Vital Signs: Preventing *Clostridium difficile* Infections Weekly, March 9, 2012;61(09):157-62.

²Clabots CR, Johnson S, Olson MM, Peterson LR, Gering DN. Acquisition of *Clostridium difficile* by hospitalized patients: evidence for colonized new admissions as a source of infection. *J. Infect Dis.* Sept 1992;166 (3):561-7.

³Ryan KJ, Ray CG (ed). *Sherris Medical Microbiology* (4th ed.) McGraw Hill. pp. 322-4.

⁴Kelly CP, LaMont JT. *Clostridium difficile*—more difficult than ever. *N. Engl. J. Med.* Oct 2008;359 (18):1932-40.

⁵Binion DG. *Clostridium difficile* and IBD. *Inflam. Bowel Dis.* Mon. 2010;11 (1):7-14.



For more information on AmpliVue C. difficile, visit our website, call your Quidel Account Manager at 858.552.1100 (outside the U.S.), or your local distributor.

Quidel Corporation Worldwide Headquarters, 10165 McKellar Court, San Diego, CA 92121 USA quidel.com